Imovax Polio (IPV) Dosing Schedule for Adults
For unvaccinated adults at increased risk of poliovirus exposure, administer a 3-dose primary series: two 0.5 mL doses given 1-2 months apart, followed by a third dose 6-12 months after the second dose. 1
Who Needs Adult IPV Vaccination
Most U.S. adults do not require routine polio vaccination, as they are already immune from childhood vaccination. However, vaccination is specifically indicated for adults at increased risk of poliovirus exposure 2:
- Travelers to countries where polio is epidemic or endemic
- Laboratory workers handling specimens that may contain polioviruses
- Healthcare workers with close contact to patients potentially excreting wild polioviruses
- Members of communities with active wild poliovirus disease
- Unvaccinated or incompletely vaccinated adults (per 2023 ACIP update) 3
Standard Primary Series Schedule
Unvaccinated Adults
The FDA-approved schedule for Imovax Polio (IPOL) in unvaccinated adults consists of 1:
- Dose 1 and 2: 0.5 mL each, separated by 1-2 months
- Dose 3: 0.5 mL given 6-12 months after dose 2
- Route: Intramuscular or subcutaneous in the deltoid area
Accelerated Schedules (When Time is Limited)
When standard intervals cannot be met before protection is needed 2, 1:
- If >8 weeks available: Give 3 doses at least 4 weeks apart
- If 4-8 weeks available: Give 2 doses at least 4 weeks apart
- If <4 weeks available: Give single dose
Important: Complete remaining doses at recommended intervals if the person remains at increased risk 2.
Previously Vaccinated Adults
Incompletely Vaccinated
Adults with fewer than 3 doses of any polio vaccine (OPV or IPV) should receive at least one 0.5 mL dose of IPV. Give additional doses as time permits to complete the primary series 1.
Completely Vaccinated
Adults who completed a primary series and are at increased risk can receive one lifetime booster dose of 0.5 mL IPV. Available data do not support the need for more than a single lifetime booster 2, 1.
Key Clinical Considerations
Administration details:
- Administer intramuscularly or subcutaneously in the deltoid area for adults
- Do NOT administer intravenously
- Can be given simultaneously with other vaccines using separate syringes at separate sites 1
Contraindications:
- Severe allergic (anaphylactic) reaction to previous IPV dose
- Anaphylactic reaction to streptomycin, polymyxin B, or neomycin (trace amounts present in vaccine) 2
Pregnancy: While no adverse effects have been documented, vaccination should theoretically be avoided. However, if a pregnant woman is at increased risk and requires immediate protection, IPV can be administered per standard adult schedules 2.
Safety profile: No serious adverse events related to enhanced-potency IPV have been documented 2.
Important Pitfalls to Avoid
- Do not assume immunity without documentation - adults without vaccination records should be considered unvaccinated 2
- Do not delay vaccination for travelers - if departure is imminent, give at least one dose even if the full series cannot be completed 2
- Do not confuse with OPV schedules - OPV is no longer routinely produced in the U.S. and is reserved only for outbreak control 2
- Do not give more than one lifetime booster to previously vaccinated adults, as additional doses beyond this are not supported by evidence 2